Highlights United Therapeutics Corporation

Stocks

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-10 EDT			5-day change	1st Jan Change
547.06 ^USD	-0.98%		-1.59%	+12.28%

07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts United Therapeutics Price Target to $613 From $620	MT

Highlights

07-02	United Therapeutics Buys Thymmune Therapeutics for $140 Million	MT
07-01	United Therapeutics Corporation acquired Thymmune Therapeutics, Inc. for $300 million.	CI
06-29	United Therapeutics' LungFX Device Gets FDA Premarket Approval	MT
06-29	United Therapeutics Corporation Announces FDA Approval of The LungFX Device For Centralized Ex Vivo Lung Perfusion	CI
05-18	United Therapeutics Corporation Publishes TETON-1 Study Results of Tyvaso in the New England Journal of Medicine and Presents At Ats	CI
05-17	United Therapeutics Corporation Announces Advance Outcomes Study Of Ralinepag Presented At ATS	CI
05-16	United Therapeutics Corporation Announces Fda Clearance to Proceed with Uheart Xenotransplantation Clinical Trial	CI
05-13	Varda Space Industries And United Therapeutics Collaborate To Advance Microgravity-Enabled Treatments For Rare Pulmonary Disease	CI
05-13	United Therapeutics, Varda to Study Space-Based Drug Manufacturing for Pulmonary Disease Treatments	MT
05-11	United Therapeutics Corporation Presents New Data from TETON-1, Advance Outcomes, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis	CI
05-06	United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	United Therapeutics Q1 Earnings, Revenue Fall	MT
05-06	Earnings Flash (UTHR) United Therapeutics Posts Q1 EPS $5.82, vs. FactSet Est of $6.91	MT
05-06	Earnings Flash (UTHR) United Therapeutics Corporation Reports Q1 Revenue $781.5M, vs. FactSet Est of $797.4M	MT
05-06	Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 9, 2026.	CI
04-08	United Therapeutics Corporation Receives Fda Regenerative Medicine Advanced Therapy Designation for Miroliverelap for Treatment of Acute Liver Failure	CI
04-08	United Therapeutics Says FDA Grants Regenerative Medicine Advanced Therapy Designation for Liver Assist Product	MT
03-30	United Therapeutics Corporation Announces Teton-1 Pivotal Study of Tyvaso Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis	CI
03-30	Top Premarket Gainers	MT
03-11	United Therapeutics Corporation Publishes Full Results Of TETON-2 Phase 3 Clinical Trial For Tyvaso Inhalation Solution	CI
03-09	United Therapeutics Corporation authorizes a Buyback Plan.	CI
03-09	United Therapeutics Corporation announces an Equity Buyback for $2,000 million worth of its shares.	CI
03-09	United Therapeutics unveils $2 bln buyback plan, launches $1.5 bln accelerated repurchase	RE
03-02	United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy	CI
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE